Alan Huang
2021
In 2021, Alan Huang earned a total compensation of $2.2M as Chief Scientific Officer at Tango Therapeutics, a 276% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $168,347 |
---|---|
Option Awards | $1,649,121 |
Salary | $394,793 |
Other | $3,396 |
Total | $2,215,657 |
Huang received $1.6M in option awards, accounting for 74% of the total pay in 2021.
Huang also received $168.3K in non-equity incentive plan, $394.8K in salary and $3.4K in other compensation.
Rankings
In 2021, Alan Huang's compensation ranked 5,657th out of 12,415 executives tracked by ExecPay. In other words, Huang earned more than 54.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,657 out of 12,415 | 54th |
Division Manufacturing | 2,397 out of 5,508 | 57th |
Major group Chemicals And Allied Products | 1,042 out of 2,378 | 56th |
Industry group Drugs | 930 out of 2,099 | 56th |
Industry Pharmaceutical Preparations | 669 out of 1,549 | 57th |
Source: SEC filing on April 26, 2022.
Huang's colleagues
We found two more compensation records of executives who worked with Alan Huang at Tango Therapeutics in 2021.